BigHat Biosciences[ PART ]
A clinical-stage, AI-driven protein therapeutics platform company
Series C$75M2026-09-23Verified against 4 of 28 sources
Named on 30 rounds in the feed, most often at Series B and in Biotech.
Rounds from 2017-09-18 to 2026-11-03
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Thryv Therapeutics Inc. A clinical-stage biotechnology company developing precision therapies for inherited channelopathies, cardiometabolic diseases and cardiomyopathies. | Series B Verified against 3 sources | $30M | 2026-11-03 | [ PART ] |
BigHat Biosciences A clinical-stage, AI-driven protein therapeutics platform company | Series C Verified against 4 of 28 sources | $75M | 2026-09-23 | [ PART ] |
SonoThera SonoThera develops innovative ultrasound-mediated nonviral genetic therapies targeting various medical conditions. | Series B Verified against 1 of 4 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $125M | 2026-06-10 | [ PART ] |
CREATE Medicines Create Medicines develops innovative immune programming therapies for treating cancer and autoimmune diseases. | Series B Verified against 2 of 4 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $122M | 2026-05-14 | [ PART ] |
Neomorph Neomorph develops molecular glue degraders to target and destroy disease-causing proteins. | Series B Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2026-04-13 | [ PART ] |
Sidewinder Therapeutics Sidewinder Therapeutics specializes in developing bispecific antibody-drug conjugates aimed at treating difficult cancers for patients. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $137M | 2026-04-08 | [ PART ] |
Solve Therapeutics Novel antibody-drug conjugates (ADCs) for cancer treatment targeted at solid tumors and optimized for payload delivery using proprietary technology. | Funding round Verified against 1 of 4 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $120M | 2025-11-17 | [ PART ] |
Nilo Nilo Therapeutics develops medicines that target neural circuits to restore immune balance in autoimmune and inflammatory disease. | Series A Verified against 1 of 4 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $101M | 2025-10-08 | [ PART ] |
Crystalys Therapeutics Crystalystx develops therapeutics specifically for treating gout. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $205M | 2025-09-30 | [ PART ] |
ArtBio ARTBIO develops alpha radioligand therapies focused on cancer treatment aimed at healthcare providers and patients. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $132M | 2025-07-29 | [ PART ] |
Neurona Therapeutics Cell therapies for targeted repair of dysfunctional neural circuits underlying chronic neurological diseases. | Funding round Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $102M | 2025-04-03 | [ PART ] |
Latigo Biotherapeutics Latigo is a clinical-stage biopharmaceutical company developing innovative non-opioid pain medicines. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $150M | 2025-03-17 | [ PART ] |
Eikon Therapeutics Eikon is a late-stage clinical biopharmaceutical company focused on inventing and developing breakthrough therapeutics for serious illnesses through innovative scientific and engineering approaches. | Series D Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $350.7M | 2025-02-26 | [ PART ] |
Umoja Biopharma Umoja Biopharma, a clinical-stage leader developing in vivo CAR T cell therapies. | Series C Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2025-01-14 | [ PART ] |
Airna AIRNA develops RNA editing therapeutics aimed at delivering functional cures for patients with rare diseases and common conditions. | Series A Verified against 1 of 6 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $60M | 2024-07-31 | [ PART ] |
Mirador Therapeutics Mirador Therapeutics focuses on developing precision medicines for immune-mediated inflammatory and fibrotic diseases. | Series A Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $400M | 2024-03-21 | [ PART ] |
Neurona Therapeutics Cell therapies for targeted repair of dysfunctional neural circuits underlying chronic neurological diseases. | Seed Developing, 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $120M | 2024-02-08 | [ PART ] |
SonoThera SonoThera develops innovative ultrasound-mediated nonviral genetic therapies targeting various medical conditions. | Series A Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $60.8M | 2022-12-05 | [ PART ] |
Novartis-partnered biotech A biotechnology company pioneering the discovery of precision covalent medicines | Series A Verified against 2 of 4 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $70M | 2022-10-14 | [ PART ] |
Odyssey Odyssey Therapeutics develops innovative therapies aimed at transforming the treatment of autoimmune and inflammatory diseases for patients. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $168M | 2022-10-13 | [ PART ] |
Dren Bio A privately held, clinical-stage biotechnology company developing first-in-class antibody therapeutics for cancer, autoimmune, and other serious diseases | Series B Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $65M | 2022-06-14 | [ PART ] |
Aspen Neuroscience Aspen Neuroscience develops personalized regenerative therapies, specifically autologous iPSC-derived cell replacement therapies for Parkinson's disease. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $147.5M | 2022-05-09 | [ PART ] |
Allotera Therapeutics Allotera Therapeutics develops allogeneic T-cell therapies targeted at treating various types of blood cancers like leukemia and lymphoma. | Series B Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $172M | 2021-07-15 | [ PART ] |
Neurona Therapeutics Cell therapies for targeted repair of dysfunctional neural circuits underlying chronic neurological diseases. | Funding round Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $41.5M | 2021-06-22 | [ PART ] |
Umoja Biopharma Umoja Biopharma, a clinical-stage leader developing in vivo CAR T cell therapies. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $210M | 2021-06-15 | [ PART ] |
Inari Innovative agricultural solutions leveraging AI and gene editing technology for plant breeding. | Series D Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $208M | 2021-05-12 | [ PART ] |
Aspen Neuroscience Aspen Neuroscience develops personalized regenerative therapies, specifically autologous iPSC-derived cell replacement therapies for Parkinson's disease. | Seed Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $6.5M | ~ 2019-12-12 | [ PART ] |
Encoded Therapeutics Encoded Therapeutics develops gene therapies targeting genetic disorders, primarily focusing on neurological conditions. | Series C Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $104M | 2019-06-26 | [ PART ] |
Inari Innovative agricultural solutions leveraging AI and gene editing technology for plant breeding. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $40M | 2018-08-09 | [ PART ] |
LifeMine LifeMine is a clinical-stage biopharmaceutical company that develops next-generation precision medicines through an innovative drug discovery approach focused on evolutionary insights from fungi, targeting patients in need of breakthrough therapies. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $55M | 2017-09-18 | [ PART ] |